- Home
- CLPR vs ANL Comparison
CLPR vs ANL Comparison
Compare CLPR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLPR | ANL |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 350.9M |
| IPO Year | 2015 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CLPR | ANL |
|---|---|---|
| Price | $3.25 | $8.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 58.6K | ★ 459.6K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $3.10 | $0.88 |
| 52 Week High | $4.68 | $12.09 |
Technical Indicators
Market Signals| Indicator | CLPR | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | 52.82 |
| Support Level | N/A | $1.36 |
| Resistance Level | $3.96 | $12.09 |
| Average True Range (ATR) | 0.15 | 0.82 |
| MACD | -0.02 | -0.47 |
| Stochastic Oscillator | 28.58 | 36.73 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.